NewsRoom Articles - BioMedWire (BMW)

FridayApr 03, 2026 10:00 am

Gallup Poll: Healthcare Returns to the Top of Americans’ Biggest Domestic Worries

According to a poll conducted by Gallup in March, Americans are most concerned about healthcare. This finding is notable given the escalation in the Iran war and the way events in the Middle East are currently dominating news headlines. Gallup conducted a poll seeking the views of Americans about how much they worry about a list of 15 policy areas on the domestic front. 61% of the respondents revealed that they are greatly worried about healthcare. The next four biggest sources of worry for Americans were connected to economic issues. Those policy issues are the state of the economy, concerns about inflation in the country, spending by…

ThursdayApr 02, 2026 10:00 am

Report Forecasts the Cancer Immunotherapy Market Hitting $311.4B by 2031

A recently published report by Mordor Intelligence analyzes future projections, growth drivers and the key trends that are shaping the rapidly growing market for cancer immunotherapy. The report puts the valuation of this market in 2025 at $144.8 billion and projects that it will expand to $311.4 billion by 2031. This expected expansion shows the extent to which patients and clinicians are increasingly accepting immunotherapy as a major approach in cancer care. As a result, these treatments are shifting from being niche therapies and are becoming recognized treatment options by the mainstream medical community and the patients they serve. The…

WednesdayApr 01, 2026 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Credibility with HyBryte Research Publication

Publishing research in peer-reviewed journals plays a central role in ensuring the credibility and reliability of scientific findings. Companies that consistently publish their findings often strengthen their credibility with both regulators and the medical community. Most recently, SNGX announced that a clinical summary of its HyBryte(TM) therapy for cutaneous T-cell lymphoma was published in the peer-reviewed journal “Expert Opinion on Investigational Drugs.” The publication of clinical research in peer-reviewed journals remains a critical milestone in drug development, offering independent validation and broader visibility for emerging therapies. Soligenix (NASDAQ: SNGX) recently reached such a milestone with the publication of a clinical summary of its HyBryte(TM)…

TuesdayMar 31, 2026 11:15 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”). LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer’s internal repair system. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by over 25 published preclinical and translational studies so far. LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.…

TuesdayMar 31, 2026 10:00 am

Researchers Discover Mechanism Behind Deadly Pediatric Brain Cancer

A team of scientists from Texas Children’s Hospital, University of Pittsburgh and Baylor College of Medicine has discovered the primary driver of a deadly pediatric brain cancer, PFA (posterior fossa type A) ependymoma. They identified male sex hormones called androgens as playing a key role in promoting PFA ependymoma growth. The study, whose findings appeared in the journal Nature, shows that androgens don’t play a part in the development of any other kind of brain tumor. The team’s work shows that when the signaling of these hormones is blocked, the growth of the tumors is blocked. This discovery creates a possibility that treatments could be developed to block these hormones to…

TuesdayMar 31, 2026 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition

In the life sciences industry, a robust pipeline is widely recognized as a critical driver of value creation and sustainability. The significance of the UK designation extends beyond a single program. The UK designation builds on additional regulatory recognition for dusquetide, including orphan drug designation from the FDA for Behçet’s disease. A strong and diversified pipeline is often the foundation of long-term success in the biotechnology sector, enabling companies to sustain innovation while advancing multiple therapeutic opportunities. Soligenix (NASDAQ: SNGX) is reinforcing that foundation as its investigational therapy SGX945 receives Promising Innovative Medicine designation in the United Kingdom, a development…

TuesdayMar 31, 2026 9:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’

Cardiovascular disease remains the leading cause of death in the United States, representing a significant and persistent healthcare burden that the company’s solutions are designed to address. Cardio Diagnostics has developed a proprietary platform that integrates epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights from a simple blood sample. The company’s clinical tests are non-invasive, require no fasting or radiation, and are designed to detect and assess coronary heart disease, including forms that may not be identified through traditional diagnostic methods. The company has established multiple commercialization channels, including provider networks, employer partnerships, and community-based programs,…

MondayMar 30, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance tumor response to treatment. LIXTE’s LB-100 is designed to sensitize cancer cells to chemotherapy and potentially enhance immune system activity, offering a complementary approach to existing treatments. The company recently announced the expansion of its ongoing clinical trial in clear cell ovarian cancer, including an increase in patient enrollment that effectively doubles the size of the study. Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need…

FridayMar 27, 2026 10:00 am

Major Discovery Could Reshape Cancer Immunotherapy

Researchers seeking new ways of fighting cancer using immunotherapy have discovered a “hidden brake” that had previously been unknown to scientists. This brake exists on immune cells and scales back their ability to combat cancer, and it acts without any influence from tumor cells. This molecule, dubbed SLAMF6, occurs naturally on fighter immune cells called T-cells. It is an inbuilt weakness on those cells and it shuts off T-cells’ capacity to kill tumor cells. In preclinical trials, the researchers turned off this switch and were able to revive the immune cells’ ability to combat cancer. The study, whose findings were…

ThursdayMar 26, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

LIXT is developing LB-100, a first-in-class therapy designed to enhance the effectiveness of established cancer treatments while cutting down toxicity Strategic partnership with Liora Technologies integrates multimodal oncology data, enabling precision-guided patient care and streamlined clinical trials These developments position the company at the intersection of innovation and therapeutics Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Gallup Poll: Healthcare Returns to the Top of Americans’ Biggest Domestic Worries

Report Forecasts the Cancer Immunotherapy Market Hitting $311.4B by 2031

Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Credibility with HyBryte Research Publication

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

Researchers Discover Mechanism Behind Deadly Pediatric Brain Cancer

Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

Major Discovery Could Reshape Cancer Immunotherapy

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search